Cowen Starts Fate Therapeutics (FATE) at Outperform

Cowen analyst Tyler Van Buren initiates coverage on Fate Therapeutics (NASDAQ: FATE) with a Outperform rating.

The analyst comments "Fate is often indiscriminately lumped into the allo CAR-T basket, but we believe its platform is differentiated via its iNK cell therapies, which are designed to synergize with SOC mAbs. This – combined with the strong safety profile of iNKs – can allow for broad utilization in various tumor types. We are initiating at Outperform given the potential of iNKs in B cell lymphomas, AML, and MM."

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $48.00 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market